Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1202-1208

  Reddy, Y Sunila ^a   Ford, Susan L ^a   Anderson, Maggie T ^a   Murray, Sharon C ^a   Ng Cashin, Judith ^a   Johnson, Mark A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRECANAVIR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DOSE INCREASE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET; TREATMENT DURATION;

ADULT; AREA UNDER CURVE; BENZODIOXOLES; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SAFETY;

EID: 34247145819     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01005-06     Document Type: Article

References (6)

1. Ford, S. L., Y. S. Reddy, M. T. Anderson, S. C. Murray, P. Fernandez, D. S. Stein, and M. A. Johnson. 2006. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 50:2201-2206.
2. Motwani, B., and W. Khayr. 2006. Pharmacoenhancement of protease inhibitors. Am. J. Ther. 13:57-63.
3. Saah, A. J., G. A. Winchell, M. L. Nessly, M. A. Seniuk, R. R. Rhodes, and P. J. Deutsch. 2001. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob. Agents Chemother. 45:2710-2715.
4. van Heeswijk, R. P., A. I. Veldkamp, R. M. Hoetelmans, J. W. Mulder, G. Schreij, A. Hsu, J. M. Lange, J. H. Beijnen, and P. L. Meenhorst. 1999. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 13:F95-F99.
5. Veldkamp, A. I., R. P. G. van Heeswijk, J. W. Mulder, P. L. Meenhorst, G. Schreij, S. van der Geest, J. M. A. Lange, J. H. Beynen, and R. M. W. Hoetelmans. 2001. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 27:344-349.
6. Wire, M. B., C. Ballow, S. L. Preston, C. W. Hendrix, P. J. Piliero, Y. Lou, and D. S. Stein. 2004. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 18:897-907.